Affiliations: [a] Bioengineering Unit, University of Strathclyde, Glasgow, UK | [b] Royal Hospital for Sick Children, Yorkhill Hospitals, Glasgow, UK | [c] Fraser of Allander Assessment Unit, Royal Hospital for Sick Children, Yorkhill Hospitals, Glasgow, UK | [d] School of Health and Social Care, Glasgow Caledonian University, Glasgow, UK
Correspondence:
[*]
Address for correspondence: Sujay Galen, Bioengineering Unit, Wolfson Centre, University of Strathclyde, 106 Rottenrow, Glasgow G4 0NW, UK. Tel.: +44 141 548 2855; Fax: +44 141 552 6098; E-mail: sujay.galen@strath.ac.uk.
Abstract: Background:Among the ambulant population of children with spastic cerebral palsy (CP), dynamic equinus is one of the most common form of gait deviation that is encountered. Objective:To investigate the combined effects of Functional Electrical Stimulation (FES) and Botulinum Toxin A (BTXA) therapy in children with spastic CP, and to demonstrate the feasibility of this combination therapy. Methods:A single-subject design with repeated measures was adopted. Eight children (six males, two females; mean age 7 y 9 mo, SD 1 y 5 mo; range 7 y to 11 y) diagnosed with hemiplegic (n=6) or diplegic (n=2) spastic CP completed the study. Each subject participated in the study for twenty weeks. This period consisted of baseline (one week), BTXA phase (three weeks), first FES phase (four weeks), first control phase (four weeks), second FES phase (four weeks) and second control phase (four weeks). Subjects were assessed at the end of each phase. The ankle angle at the end of swing phase was selected as the primary outcome measure. The secondary outcome measure recorded was the foot contact pattern. Results:There was an increase in ankle dorsiflexion at the end of the combined intervention in most subjects (n=6), accompanied by an improvement in foot contact pattern. Conclusions:This pilot study demonstrated that it is feasible to combine BTXA therapy with FES in ambulant children with spastic CP.
